Featured 13F manager
Farallon Capital Management, L.l.c.
San Francisco, CA 87 processed 13Fs on this site · 2021 Q3–2026 Q2
- $21.7B
- 77 Positions
- 2026 Q2
- +23.6% QoQ
- Top 5 29.9%
Portfolio
top 5 29.9% · top 10 44.0%
- RVMD - Revolution Medicines 11.7%
- EA - Electronic Arts 7.5%
- BBIO - Bridgebio Pharma 3.7%
- PTGX - Protagonist Therapeutics 3.6%
- EXEL - Exelixis 3.4%
- LQDA - Liquidia 3.1%
- AMZN - Amazon 2.9%
- LNTH - Lantheus 2.9%
- NTRA - Natera 2.8%
- UNH - Unitedhealth Group 2.4%
- TMO - Thermo Fisher Scientific 2.4%
- ROIV - Roivant Sciences 2.3%
- Other 51.3%
AUM over time
Book
| CRM - Salesforce | 3.96% | Reduce −7.4% | 3,501,838 | $199.78 | $700M | −279,000 | +$198M |
| IQV - IQVIA | 3.61% | Reduce −1.5% | 3,208,112 | $198.89 | $638M | −50,000 | −$29M |
| TMO - Thermo Fisher Scientific | 3.42% | Reduce −9.7% | 1,049,059 | $576.37 | $605M | −112,900 | −$35M |
| Horizon Therapeutics Pub L | 3.35% | New | 5,419,823 | $109.14 | $592M | +5,419,823 | +$592M |
| GOOG - Alphabet · CL C | 3.21% | Add +80.3% | 5,456,140 | $104.00 | $567M | +2,430,000 | +$299M |
| TRU - Transunion | 3.03% | Reduce −2.8% | 8,611,593 | $62.14 | $535M | −252,302 | +$32M |
| MSFT - Microsoft | 2.72% | Reduce −1.2% | 1,667,478 | $288.30 | $481M | −21,000 | +$76M |
| Shaw Communications · CL B | 2.68% | New | 15,800,000 | $29.92 | $473M | +15,800,000 | +$473M |
| EXEL - Exelixis | 2.58% | Add +115.9% | 23,466,000 | $19.41 | $455M | +12,597,851 | +$281M |
| UNH - Unitedhealth Group | 2.32% | New | 866,000 | $472.59 | $409M | +866,000 | +$409M |
| AZNN — | 2.30% | Reduce −0.2% | 5,867,553 | $69.41 | $407M | −8,909 | +$9M |
| INTU - Intuit | 2.30% | Add +1.0% | 911,000 | $445.83 | $406M | +8,900 | +$55M |
| ARMK - Aramark | 2.28% | Add +3.8% | 11,237,884 | $35.80 | $402M | +409,000 | −$45M |
| SPGI - S&P Global | 2.25% | Add +6.9% | 1,151,900 | $344.77 | $397M | +74,800 | +$36M |
| BSX - Boston Scientific | 2.18% | Reduce −16.8% | 7,705,257 | $50.03 | $385M | −1,555,000 | −$43M |
| YMM - Full Truck Alliance | 1.89% | Add +0.8% | 43,805,238 | $7.61 | $333M | +365,495 | −$14M |
| DT - Dynatrace | 1.86% | Reduce −1.6% | 7,788,269 | $42.30 | $329M | −130,000 | +$26M |
| NOW - Servicenow | 1.84% | Add +4.6% | 699,650 | $464.72 | $325M | +31,000 | +$66M |
| ELV - Elevance Health | 1.75% | Add +6.2% | 673,630 | $459.81 | $310M | +39,330 | −$16M |
| CNC - Centene Del | 1.71% | Add +4.0% | 4,774,775 | $63.21 | $302M | +183,234 | −$75M |
| HWM - Howmet Aerospace | 1.66% | Reduce −14.4% | 6,941,527 | $42.37 | $294M | −1,165,826 | −$25M |
| SHW - Sherwin Williams | 1.66% | Reduce −5.7% | 1,306,792 | $224.77 | $294M | −79,000 | −$35M |
| WAB - Wabtec | 1.63% | Add +4.4% | 2,857,930 | $101.06 | $289M | +120,000 | +$16M |
| EFX - Equifax | 1.60% | Reduce −18.0% | 1,396,597 | $202.84 | $283M | −305,900 | −$48M |
| BX - Blackstone | 1.56% | Reduce −3.4% | 3,139,951 | $87.84 | $276M | −109,000 | +$35M |
| MA - Mastercard · CL A | 1.49% | Reduce −20.7% | 726,471 | $363.41 | $264M | −189,700 | −$55M |
| AON - AON PLC · CL A | 1.44% | Add +2.1% | 804,686 | $315.29 | $254M | +16,600 | +$17M |
| NYT - New York Times · CL A | 1.40% | Add +4.7% | 6,354,791 | $38.88 | $247M | +286,000 | +$50M |
| CSGP - Costar Group | 1.33% | Add +49.6% | 3,411,185 | $68.85 | $235M | +1,131,000 | +$59M |
| V - VISA · CL A | 1.29% | Reduce −19.2% | 1,009,410 | $225.46 | $228M | −239,600 | −$32M |
| XYZ - Block · CL A | 1.11% | Reduce −11.1% | 2,861,050 | $68.65 | $196M | −356,950 | −$6M |
| BABA - Alibaba Group | 1.04% | Reduce −32.4% | 1,800,000 | $102.18 | $184M | −861,000 | −$50M |
| Oak Str Health | 0.99% | New | 4,503,076 | $38.68 | $174M | +4,503,076 | +$174M |
| BIIB - Biogen | 0.98% | Add +4.6% | 619,798 | $278.03 | $172M | +27,099 | +$8M |
| UTHR - United Therapeutics | 0.84% | Add +1.4% | 664,767 | $223.96 | $149M | +8,894 | −$34M |
| Sarepta Therapeutics | 0.71% | Reduce −1.7% | 913,300 | $137.83 | $126M | −15,600 | +$6M |
| HUM - Humana | 0.67% | Reduce −9.5% | 244,661 | $485.46 | $119M | −25,739 | −$20M |
| Prometheus Biosciences | 0.67% | Add +658.7% | 1,100,806 | $107.32 | $118M | +955,706 | +$102M |
| Masimo | 0.66% | Reduce −16.7% | 631,649 | $184.54 | $117M | −126,851 | +$4M |
| BEAM - Beam Therapeutics | 0.59% | Add +0.9% | 3,431,921 | $30.62 | $105M | +32,000 | −$28M |
| BEKE - KE | 0.51% | Reduce −17.4% | 4,758,500 | $18.84 | $90M | −1,000,000 | +$9M |
| PCG - Pg And E | 0.46% | Reduce −2.9% | 5,005,142 | $16.17 | $81M | −150,000 | −$3M |
| Lufax · CL A | 0.44% | Reduce −0.4% | 38,296,543 | $2.04 | $78M | −139,856 | +$4M |
| PACB — | 0.42% | Add +58.7% | 6,355,120 | $11.58 | $74M | +2,350,720 | +$41M |
| RVMD - Revolution Medicines | 0.40% | Add +93.4% | 3,283,600 | $21.66 | $71M | +1,585,585 | +$31M |
| ENTA - Enanta Pharmaceuticals | 0.35% | Hold | 1,550,000 | $40.44 | $63M | — | — |
| PTGX - Protagonist Therapeutics | 0.34% | Reduce −28.4% | 2,615,014 | $23.00 | $60M | −1,036,873 | +$20M |
| INSP - Inspire Med Sys | 0.32% | Hold | 242,596 | $234.07 | $57M | — | — |
| AGIO - Agios Pharmaceuticals | 0.27% | Add +3.3% | 2,092,829 | $22.97 | $48M | +67,000 | −$9M |
| HCA - Hca Healthcare | 0.23% | New | 156,600 | $263.68 | $41M | +156,600 | +$41M |
| MDGL - Madrigal Pharmaceuticals | 0.22% | Add +7.1% | 163,819 | $242.26 | $40M | +10,819 | −$5M |
| BRKR - Bruker | 0.22% | Reduce −42.5% | 494,476 | $78.84 | $39M | −364,824 | −$20M |
| EVH - Evolent Health · CL A | 0.21% | Add +278.8% | 1,143,909 | $32.45 | $37M | +841,909 | +$29M |
| NTRA - Natera | 0.21% | Add +362.1% | 661,783 | $55.52 | $37M | +518,583 | +$31M |
| CYTK - Cytokinetics | 0.19% | Reduce −44.9% | 938,072 | $35.19 | $33M | −763,666 | −$45M |
| Reata Pharmaceuticals · CL A | 0.17% | Reduce −2.1% | 325,000 | $90.92 | $30M | −7,000 | +$17M |
| Holding · CL A | 0.16% | Hold | 2,809,000 | $10.15 | $29M | — | — |
| Metals Acquisition · CL A | 0.14% | Hold | 2,489,700 | $10.22 | $25M | — | — |
| Berenson Acquisition I · CL A | 0.14% | Hold | 2,475,000 | $10.05 | $25M | — | — |
| THC - Tenet Healthcare | 0.13% | New | 389,000 | $59.42 | $23M | +389,000 | +$23M |
| JAZZ - Jazz Pharmaceuticals | 0.12% | Reduce −34.7% | 150,000 | $146.33 | $22M | −79,800 | −$15M |
| Savara | 0.12% | Add +7.6% | 10,908,086 | $1.95 | $21M | +773,125 | +$6M |
| APLSUSD - Apellis Pharmaceuticals | 0.12% | Reduce −29.5% | 317,553 | $65.96 | $21M | −132,847 | −$2M |
| Maxar Technologies | 0.12% | New | 400,000 | $51.06 | $20M | +400,000 | +$20M |
| Swiftmerge Acquisition · CLASS A | 0.12% | Hold | 1,980,000 | $10.32 | $20M | — | — |
| Zymeworks | 0.10% | Add +33.3% | 2,000,000 | $9.04 | $18M | +500,000 | +$6M |
| Sdcl Edge Acquisition · CL A | 0.10% | Hold | 1,732,500 | $10.27 | $18M | — | — |
| BNTX - Biontech Se | 0.10% | Reduce −1.7% | 137,644 | $124.57 | $17M | −2,356 | −$4M |
| Syneos Health · CL A | 0.10% | New | 472,000 | $35.62 | $17M | +472,000 | +$17M |
| LNTH - Lantheus | 0.09% | New | 184,000 | $82.56 | $15M | +184,000 | +$15M |
| Ares Acquisition · CL A | 0.08% | Hold | 1,425,000 | $10.32 | $15M | — | — |
| AVTR - Avantor | 0.08% | Add +28.9% | 681,418 | $21.14 | $14M | +152,954 | +$3M |
| Holding · CLASS A | 0.08% | Hold | 1,360,040 | $10.22 | $14M | — | — |
| Tcv Acquisition · CL A | 0.07% | Hold | 1,211,459 | $10.24 | $12M | — | — |
| Iveric Bio | 0.07% | Reduce −66.8% | 484,799 | $24.33 | $12M | −977,201 | −$20M |
| Broadmark Rlty Cap | 0.06% | Reduce −49.7% | 2,437,995 | $4.70 | $11M | −2,412,005 | −$6M |
| Tpg Pace Beneficial Ii | 0.06% | Hold | 1,116,833 | $9.97 | $11M | — | — |
| COGT - Cogent Biosciences | 0.06% | Add +1055.1% | 983,452 | $10.79 | $11M | +898,313 | +$10M |
| BHVN - Biohaven | 0.06% | Reduce −25.0% | 750,000 | $13.66 | $10M | −250,000 | −$4M |
| Screaming Eagle Acquisitn · CLASS A | 0.06% | Hold | 1,000,000 | $10.15 | $10M | — | — |
| Churchill Capital Vii · CL A | 0.06% | Hold | 1,000,000 | $10.14 | $10M | — | — |
| Churchill Capital Vi · CL A | 0.06% | Hold | 997,767 | $10.11 | $10M | — | — |
| Cara Therapeutics | 0.06% | Reduce −3.8% | 1,995,370 | $4.91 | $10M | −78,830 | −$12M |
| Holding · CL A | 0.05% | Hold | 900,000 | $10.50 | $9M | — | — |
| RIO - Rio Tinto | 0.05% | New | 137,500 | $68.60 | $9M | +137,500 | +$9M |
| Holding | 0.05% | Hold | 848,184 | $10.12 | $9M | — | — |
| Holding · CL A | 0.05% | Hold | 775,200 | $10.42 | $8M | — | — |
| Holding · CL A | 0.04% | Hold | 750,000 | $10.25 | $8M | — | — |
| Panacea Acquisition Ii · CL A | 0.04% | Hold | 750,000 | $10.20 | $8M | — | — |
| Holding · CLASS A | 0.04% | Hold | 745,000 | $10.23 | $8M | — | — |
| Corsair Partnering · CL A | 0.04% | Hold | 700,000 | $10.26 | $7M | — | — |
| Khosla Ventures Acquisition · CL A | 0.04% | Hold | 700,000 | $10.14 | $7M | — | — |
| ALVO - Alvotech | 0.04% | Hold | 500,000 | $12.90 | $6M | — | — |
| Rcf Acquisition · CL A | 0.04% | Hold | 600,000 | $10.46 | $6M | — | — |
| VYGR - Voyager Therapeutics | 0.03% | New | 797,000 | $7.71 | $6M | +797,000 | +$6M |
| SLAM · CL A | 0.03% | Hold | 570,396 | $10.33 | $6M | — | — |
| VNET - VNET Group | 0.03% | Hold | 1,775,000 | $3.24 | $6M | — | — |
| Blue Whale Acquisition · CLASS A | 0.03% | Hold | 575,000 | $9.94 | $6M | — | — |
| ICE - Intercontinental Exchange | 0.03% | New | 51,832 | $104.29 | $5M | +51,832 | +$5M |
| Holding | 0.03% | Add +92.5% | 1,560,500 | $3.39 | $5M | +750,000 | +$3M |
| Tio Tech A · CLASS A | 0.03% | Hold | 502,001 | $10.18 | $5M | — | — |
| Gores Ix · CLASS A | 0.03% | Hold | 500,000 | $10.08 | $5M | — | — |
| Atento S A | 0.03% | Hold | 2,230,357 | $2.08 | $5M | — | — |
| Lamf Global Ventures I · CLASS A | 0.02% | Hold | 400,000 | $10.45 | $4M | — | — |
| Finserv Acquisition Ii · CL A | 0.02% | Reduce −33.3% | 400,000 | $10.09 | $4M | −200,000 | −$2M |
| Forest Road Acquisition Cor · CL A | 0.02% | Reduce −68.0% | 400,000 | $9.94 | $4M | −850,000 | −$9M |
| Cartica Acquisition · CLASS A | 0.02% | Hold | 350,000 | $10.54 | $4M | — | — |
| Holding · CLASS A | 0.02% | Hold | 350,000 | $10.37 | $4M | — | — |
| Uta Acquisition · CLASS A | 0.02% | Hold | 344,100 | $10.41 | $4M | — | — |
| Ambrx Biopharma | 0.02% | New | 361,000 | $8.92 | $3M | +361,000 | +$3M |
| Sound Point Acquisition · CLASS A | 0.02% | Hold | 300,000 | $10.55 | $3M | — | — |
| Avrobio | 0.02% | Add +321.1% | 3,116,000 | $1.00 | $3M | +2,376,000 | +$3M |
| NUVB - Nuvation Bio · CL A | 0.01% | Reduce −30.8% | 1,465,000 | $1.66 | $2M | −652,600 | −$2M |
| Provention Bio | 0.01% | New | 90,000 | $24.10 | $2M | +90,000 | +$2M |
| Arya Sciences Acqu Iv · CL A | 0.01% | Reduce −75.0% | 200,000 | $10.32 | $2M | −600,000 | −$6M |
| Marblegate Acquisition · CL A | 0.01% | Hold | 150,000 | $10.07 | $2M | — | — |
| ALNY - Alnylam Pharmaceuticals | 0.01% | Reduce −94.8% | 6,719 | $200.32 | $1M | −123,337 | −$30M |
| Blueprint Medicines | 0.01% | Reduce −76.1% | 22,420 | $44.99 | $1M | −71,580 | −$3M |
| NTRS - Northern Trust · CL A | 0.01% | Hold | 100,000 | $10.07 | $1M | — | — |
| OKLO - Altc Acquisition · CL A | 0.01% | Hold | 98,300 | $10.15 | $998K | — | — |
| Amyris | 0.01% | Reduce −29.3% | 706,700 | $1.36 | $961K | −293,300 | −$569K |
| Summit Midstream Partners | 0.01% | Add +35.2% | 58,214 | $15.35 | $894K | +15,159 | +$175K |
| Legend Biotech | 0.00% | Reduce −97.6% | 17,600 | $48.22 | $849K | −729,014 | −$36M |
| Clever Leaves | 0.00% | Reduce −27.8% | 1,927,945 | $0.3819 | $736K | −740,606 | −$83K |
| Better Therapeutics | 0.00% | Reduce −14.1% | 699,042 | $0.7280 | $509K | −114,514 | −$402K |
| EDU — | 0.00% | Hold | 13,000 | $38.61 | $502K | — | — |
| Karuna Therapeutics | 0.00% | Hold | 2,200 | $181.64 | $400K | — | — |
Showing top 50 of 127 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2022 Q4
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| ABBV - Abbvie | 0.99% | Exit | 0 | $161.61 | $152M | −939,212 | −$152M |
| CLVT - Clarivate | 0.83% | Exit | 0 | $8.34 | $127M | −15,177,433 | −$127M |
| CVS - Cvs Health | 0.42% | Exit | 0 | $93.19 | $65M | −694,259 | −$65M |
| Holding · CLASS A | 0.12% | Exit | 0 | $10.02 | $19M | −1,900,000 | −$19M |
| Vector Acquisition Ii · CL A | 0.11% | Exit | 0 | $10.10 | $17M | −1,700,000 | −$17M |
| Disruptive Acquisition · CLASS A | 0.09% | Exit | 0 | $10.08 | $14M | −1,400,000 | −$14M |
| Agile Growth · CLASS A | 0.08% | Exit | 0 | $10.09 | $12M | −1,200,000 | −$12M |
| Holding · CL A | 0.07% | Exit | 0 | $10.10 | $11M | −1,120,102 | −$11M |
| FHN - First Horizon | 0.07% | Exit | 0 | $24.50 | $11M | −455,000 | −$11M |
| Holding · CLASS A | 0.07% | Exit | 0 | $10.10 | $10M | −1,000,000 | −$10M |
| Forum Merger Iv · CLASS A | 0.07% | Exit | 0 | $10.05 | $10M | −1,000,000 | −$10M |
| GPOR - Gulfport Energy | 0.06% | Exit | 0 | $73.64 | $9M | −116,020 | −$9M |
| Holding · CLASS A | 0.06% | Exit | 0 | $10.08 | $8M | −835,638 | −$8M |
| Holding · CL A | 0.05% | Exit | 0 | $10.10 | $8M | −800,000 | −$8M |
| Levere · CLASS A | 0.05% | Exit | 0 | $10.09 | $8M | −800,000 | −$8M |
| Holding · CLASS A | 0.05% | Exit | 0 | $10.25 | $8M | −750,000 | −$8M |
| Holding · CL A | 0.05% | Exit | 0 | $10.09 | $8M | −750,000 | −$8M |
| Pathfinder Acquisition · CL A | 0.05% | Exit | 0 | $10.07 | $8M | −750,000 | −$8M |
| Holding · CL A | 0.05% | Exit | 0 | $10.08 | $7M | −700,000 | −$7M |
| Rocket Internet Grwt Oprt · CL A | 0.04% | Exit | 0 | $10.10 | $7M | −647,945 | −$7M |
| Holding · CLASS A | 0.04% | Exit | 0 | $10.25 | $6M | −600,000 | −$6M |
| Ftac Hera Acquisition · CLASS A | 0.03% | Exit | 0 | $10.12 | $5M | −500,000 | −$5M |
| G Squared Ascend I · CL A | 0.03% | Exit | 0 | $10.11 | $5M | −500,000 | −$5M |
| Holding · CL A | 0.03% | Exit | 0 | $10.07 | $5M | −500,000 | −$5M |
| Generation Bio | 0.03% | Exit | 0 | $3.93 | $5M | −1,249,382 | −$5M |
| Holding · CL A | 0.03% | Exit | 0 | $9.85 | $5M | −484,709 | −$5M |
| Scion Tech Growth Ii · CL A | 0.03% | Exit | 0 | $10.12 | $5M | −450,000 | −$5M |
| Ldh Growth I · CLASS A | 0.03% | Exit | 0 | $10.07 | $4M | −436,702 | −$4M |
| Svf Investment · CL A | 0.03% | Exit | 0 | $10.11 | $4M | −425,000 | −$4M |
| Vpc Impact Acquisition · CLASS A | 0.03% | Exit | 0 | $10.11 | $4M | −425,000 | −$4M |
| Holding · CL A | 0.03% | Exit | 0 | $10.16 | $4M | −400,000 | −$4M |
| Holding · CLASS A | 0.03% | Exit | 0 | $10.05 | $4M | −400,000 | −$4M |
| Holding · CLASS A | 0.02% | Exit | 0 | $10.29 | $3M | −300,000 | −$3M |
| Lazard Growth Acquisition · CL A | 0.02% | Exit | 0 | $10.11 | $3M | −300,000 | −$3M |
| Live Oak Mobility Acquisi · CL A | 0.02% | Exit | 0 | $10.06 | $3M | −250,000 | −$3M |
| Arctos Northstar Acquis · CL A | 0.01% | Exit | 0 | $10.09 | $2M | −200,000 | −$2M |
| TNGX - Tango Therapeutics | 0.01% | Exit | 0 | $7.25 | $2M | −270,000 | −$2M |
| Priveterra Acquisition · CL A | 0.01% | Exit | 0 | $10.05 | $2M | −150,000 | −$2M |
| NTRS - Northern Trust · CL A | 0.01% | Exit | 0 | $10.05 | $1M | −100,000 | −$1M |
| Opal Fuels · CLASS A | — | Exit | 0 | $7.28 | $260K | −35,725 | −$260K |
| Holding | — | Exit | 0 | $2.67 | $229K | −85,838 | −$229K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 89 | $21.7B | +23.6% | 13F-HR | 8/14/2026 | 000090883426000432 |
| 2026 Q1 | 1 | $1.5B | — | new holds | 8/14/2026 | 000090883426000434 |
| 2026 Q1 | 172 | $17.5B | −17.2% | 13F-HR | 5/15/2026 | 000090883426000240 |
| 2025 Q4 | 1 | $1B | — | new holds | 8/14/2026 | 000090883426000433 |
| 2025 Q4 | 2 | $884M | — | new holds | 5/15/2026 | 000090883426000241 |
| 2025 Q4 | 151 | $21.2B | −13.2% | 13F-HR | 2/17/2026 | 000090883426000087 |
| 2025 Q3 | 144 | $24.4B | — | RESTATEMENT | 2/17/2026 | 000090883426000086 |
| 2025 Q3 | 144 | $24.4B | +5.4% | 13F-HR | 11/14/2025 | 000090883425000353 |
| 2025 Q2 | 1 | $140M | — | new holds | 2/17/2026 | 000090883426000085 |
| 2025 Q2 | 3 | $483M | — | new holds | 11/14/2025 | 000090883425000352 |
| 2025 Q2 | 141 | $23.2B | +29.2% | 13F-HR | 8/14/2025 | 000090883425000248 |
| 2025 Q1 | 1 | $274M | — | new holds | 2/17/2026 | 000090883426000084 |
| 2025 Q1 | 3 | $416M | — | new holds | 11/14/2025 | 000090883425000351 |
| 2025 Q1 | 7 | $2.2B | — | new holds | 8/14/2025 | 000090883425000247 |
| 2025 Q1 | 135 | $17.9B | −9.0% | 13F-HR | 5/15/2025 | 000090883425000177 |
| 2024 Q4 | 1 | $85M | — | new holds | 2/17/2026 | 000090883426000083 |
| 2024 Q4 | 2 | $349M | — | new holds | 11/14/2025 | 000090883425000350 |
| 2024 Q4 | 6 | $2.3B | — | new holds | 8/14/2025 | 000090883425000246 |
| 2024 Q4 | 4 | $333M | — | new holds | 5/15/2025 | 000090883425000180 |
| 2024 Q4 | 138 | $19.7B | −3.5% | 13F-HR | 2/14/2025 | 000090883425000081 |
| 2024 Q3 | 1 | $145M | — | new holds | 11/14/2025 | 000090883425000349 |
| 2024 Q3 | 6 | $1.5B | — | new holds | 8/14/2025 | 000090883425000243 |
| 2024 Q3 | 3 | $216M | — | new holds | 5/15/2025 | 000090883425000179 |
| 2024 Q3 | 2 | $544M | — | new holds | 2/14/2025 | 000090883425000080 |
| 2024 Q3 | 153 | $20.4B | −3.6% | 13F-HR | 11/14/2024 | 000090883424000307 |
| 2024 Q2 | 1 | $120M | — | new holds | 11/14/2025 | 000090883425000348 |
| 2024 Q2 | 5 | $1.2B | — | new holds | 8/14/2025 | 000090883425000245 |
| 2024 Q2 | 1 | $199M | — | new holds | 5/15/2025 | 000090883425000178 |
| 2024 Q2 | 2 | $452M | — | new holds | 2/14/2025 | 000090883425000079 |
| 2024 Q2 | 1 | $149M | — | new holds | 11/14/2024 | 000090883424000324 |
| 2024 Q2 | 157 | $21.2B | −4.2% | 13F-HR | 8/14/2024 | 000090883424000200 |
| 2024 Q1 | 1 | $93M | — | new holds | 11/14/2025 | 000090883425000347 |
| 2024 Q1 | 4 | $1.2B | — | new holds | 8/14/2025 | 000090883425000244 |
| 2024 Q1 | 2 | $159M | — | new holds | 2/14/2025 | 000090883425000078 |
| 2024 Q1 | 1 | $45M | — | new holds | 8/14/2024 | 000090883424000202 |
| 2024 Q1 | 167 | $22.1B | — | RESTATEMENT | 5/24/2024 | 000090883424000159 |
| 2024 Q1 | 167 | $22.1B | +9.8% | 13F-HR | 5/15/2024 | 000090883424000135 |
| 2023 Q4 | 1 | $65M | — | new holds | 11/14/2025 | 000090883425000346 |
| 2023 Q4 | 2 | $548M | — | new holds | 8/14/2025 | 000090883425000250 |
| 2023 Q4 | 5 | $1.1B | — | new holds | 5/15/2024 | 000090883424000141 |
| 2023 Q4 | 150 | $20.1B | +1.0% | 13F-HR | 2/14/2024 | 000090883424000070 |
| 2023 Q3 | 1 | $40M | — | new holds | 11/14/2025 | 000090883425000345 |
| 2023 Q3 | 1 | $40M | — | new holds | 5/15/2024 | 000090883424000138 |
| 2023 Q3 | 2 | $1.4B | — | new holds | 2/14/2024 | 000090883424000077 |
| 2023 Q3 | 1 | $1.9B | — | new holds | 2/12/2024 | 000090883424000049 |
| 2023 Q3 | 159 | $20B | +11.5% | 13F-HR | 11/14/2023 | 000090883423000150 |
| 2023 Q2 | 2 | $669M | — | new holds | 2/14/2024 | 000090883424000076 |
| 2023 Q2 | 5 | $1.4B | — | new holds | 11/14/2023 | 000090883423000157 |
| 2023 Q2 | 1 | $1.2B | — | new holds | 10/26/2023 | 000090883423000134 |
| 2023 Q2 | 165 | $17.9B | +1.3% | 13F-HR | 8/14/2023 | 000090883423000109 |
| 2023 Q1 | 2 | $234M | — | new holds | 2/14/2024 | 000090883424000075 |
| 2023 Q1 | 3 | $389M | — | new holds | 11/14/2023 | 000090883423000156 |
| 2023 Q1 | 1 | $15M | — | new holds | 8/14/2023 | 000090883423000110 |
| 2023 Q1 | 187 | $17.7B | +15.8% | 13F-HR | 5/15/2023 | 000117570723000127 |
| 2022 Q4 | 1 | $171M | — | new holds | 2/14/2024 | 000090883424000074 |
| 2022 Q4 | 3 | $485M | — | new holds | 11/14/2023 | 000090883423000155 |
| 2022 Q4 | 7 | $1B | — | new holds | 5/15/2023 | 000117570723000136 |
| 2022 Q4 | 232 | $15.3B | −9.3% | 13F-HR | 2/14/2023 | 000117570723000051 |
| 2022 Q3 | 1 | $125M | — | new holds | 2/14/2024 | 000090883424000073 |
| 2022 Q3 | 3 | $415M | — | new holds | 11/14/2023 | 000090883423000154 |
| 2022 Q3 | 5 | $411M | — | new holds | 5/15/2023 | 000117570723000135 |
| 2022 Q3 | 4 | $434M | — | new holds | 2/14/2023 | 000090966123000005 |
| 2022 Q3 | 298 | $16.8B | +3.5% | 13F-HR | 11/14/2022 | 000156761922019851 |
| 2022 Q2 | 1 | $115M | — | new holds | 2/14/2024 | 000090883424000081 |
| 2022 Q2 | 3 | $411M | — | new holds | 11/14/2023 | 000090883423000153 |
| 2022 Q2 | 2 | $337M | — | new holds | 5/15/2023 | 000117570723000134 |
| 2022 Q2 | 3 | $136M | — | new holds | 2/14/2023 | 000090966123000003 |
| 2022 Q2 | 9 | $1.2B | — | new holds | 11/14/2022 | 000156761922019862 |
| 2022 Q2 | 297 | $16.3B | −13.7% | 13F-HR | 8/15/2022 | 000156761922015953 |
| 2022 Q1 | 1 | $268M | — | new holds | 11/14/2023 | 000090883423000152 |
| 2022 Q1 | 1 | $314M | — | new holds | 5/15/2023 | 000117570723000133 |
| 2022 Q1 | 1 | $27M | — | new holds | 2/14/2023 | 000090966123000002 |
| 2022 Q1 | 3 | $186M | — | new holds | 11/14/2022 | 000156761922019864 |
| 2022 Q1 | 8 | $1.1B | — | new holds | 8/15/2022 | 000156761922015972 |
| 2022 Q1 | 307 | $18.8B | +0.4% | 13F-HR | 5/16/2022 | 000156761922010736 |
| 2021 Q4 | 1 | $227M | — | new holds | 5/15/2023 | 000117570723000132 |
| 2021 Q4 | 1 | $7M | — | new holds | 11/14/2022 | 000156761922019852 |
| 2021 Q4 | 1 | $115M | — | new holds | 8/15/2022 | 000156761922015968 |
| 2021 Q4 | 2 | $98M | — | new holds | 5/19/2022 | 000156761922011257 |
| 2021 Q4 | 6 | $833M | — | new holds | 5/16/2022 | 000156761922010757 |
| 2021 Q4 | 289 | $18.7B | −5.1% | 13F-HR | 2/14/2022 | 000156761922003965 |
| 2021 Q3 | 1 | $182M | — | new holds | 5/15/2023 | 000117570723000131 |
| 2021 Q3 | 1 | $105M | — | new holds | 8/15/2022 | 000156761922015964 |
| 2021 Q3 | 1 | $57M | — | new holds | 5/19/2022 | 000156761922011256 |
| 2021 Q3 | 3 | $998M | — | new holds | 5/16/2022 | 000156761922010753 |
| 2021 Q3 | 2 | $344M | — | new holds | 2/14/2022 | 000156761922003981 |
| 2021 Q3 | 293 | $19.7B | — | 13F-HR | 11/15/2021 | 000095012321015168 |
About
FARALLON CAPITAL MANAGEMENT, L.L.C.
87 processed 13Fs on this site · 2021 Q3–2026 Q2